No GRASE For Ibuprofen, No Future In OTC Internal Analgesic Monograph
This article was originally published in The Pink Sheet & The Rose Sheet
Executive Summary
Nonprescription products containing ibuprofen can now only be marketed in the US through NDAs. No companies took advantage of a proposed ibuprofen addition to the the internal analgesic, antipyretic and antirheumatic OTC monograph, issued in 2002.
You may also be interested in...
OTC Decisions In April: Naproxen CV Risk Warning, Sun US Line Rises, Perrigo Omeprazole 'Melt In Mouth' Flag
The first US approvals for adding cardiovascular risk warnings to OTC naproxenb products were for the Aleve line of multiple formulations and delivery formats and in multiple container sizes and Biopharma and Catalent 220-mg capsules. Sun Pharma extends into expectorant/allergy and diarrhea remedy spaces in US OTC market.
OTC Naproxen Labeling: US FDA Advisory Panel Finds Imprecise Direction In PRECISION
Safety study of celecoxib vs. ibuprofen and naproxen spurs advisory committees to recommend adding aspirin-interaction warning on OTC naproxen labels, but many panelist made clear that PRECISION results had not swayed their thinking on celecoxib CV safety or on the OTC ingredients' interaction with aspirin.
OTC NSAIDs Need Additional Label Warnings – FDA Advisory Panel
Labels for over-the-counter NSAIDS need additional information about potential risks, panel members in a joint meeting of FDA’s Arthritis and Drug Safety and Risk Management advisory committees say. Data do not show naproxen has a lower CV thrombotic event risk compared to other NSAIDs, they say.